Skip Nav Destination
Issues
1 April 2017
-
Cover Image
Cover Image
The estimated trillions of microbes that inhabit the human body establish a beneficial relationship with the host, but it is clear that dysbiotic relationships can develop, some of which are thought to result in the development of inflammatory diseases and cancers. Several case-control metagenomics studies suggest that dysbiosis in the commensal microbiota is associated with inflammatory disorders and various cancer types throughout the body. The cover image is an artist's adaptation of a portion of Figure 1 from the Review in this issue, “The Human Microbiome and Cancer,” by Nelson and colleagues (beginning on page 226) and depicts the injection of effector cells by microbes (e.g., H. pylori) with subsequent modulation of various pathways, including Wnt/β-catenin and autophagy, to promote carcinogenesis. One mechanistic link between the microbiome and cancer is via the immune system, as the resident microbiota plays an essential role in activating, training, and modulating the host immune response. Immunological dysregulation is likely to provide mechanistic explanations as to how our microbiome influences cancer development and cancer therapies. The review discusses the complex connection between the human gut microbiome and cancer as well as the feasibility of developing novel cancer diagnostics based on microbiome profiles. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1940-6207
EISSN 1940-6215
Issue Sections
Editorial
Minireview
Research Articles
Metabolic Obesity, Adipose Inflammation and Elevated Breast Aromatase in Women with Normal Body Mass Index
Neil M. Iyengar; Kristy A. Brown; Xi Kathy Zhou; Ayca Gucalp; Kotha Subbaramaiah; Dilip D. Giri; Heba Zahid; Priya Bhardwaj; Nils K. Wendel; Domenick J. Falcone; Hanhan Wang; Samantha Williams; Michael Pollak; Monica Morrow; Clifford A. Hudis; Andrew J. Dannenberg
Responsiveness of Brca1 and Trp53 Deficiency–Induced Mammary Preneoplasia to Selective Estrogen Modulators versus an Aromatase Inhibitor in Mus musculus
Sahar J. Alothman; Weisheng Wang; David S. Goerlitz; Md Islam; Xiaogang Zhong; Archana Kishore; Redha I. Azhar; Bhaskar V. Kallakury; Priscilla A. Furth
Author Choice
Loss of BRCA1 in the Cells of Origin of Ovarian Cancer Induces Glycolysis: A Window of Opportunity for Ovarian Cancer Chemoprevention
Tatsuyuki Chiyoda; Peter C. Hart; Mark A. Eckert; Stephanie M. McGregor; Ricardo R. Lastra; Ryuji Hamamoto; Yusuke Nakamura; S. Diane Yamada; Olufunmilayo I. Olopade; Ernst Lengyel; Iris L. Romero
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.